I am surprised by this, however there is some fairly obvious reasons. Any ceo that make bold near term accomplishments and fails is facing the chopping block. The drop in the sp certainly filled the inboxes of mgmt and the bod with deep concerns. My assumption was that Nader called the conference call, the board stopped it because Nader has nothing but carrots to hold in front of investors. This is not enough and they said that’s it. Any piblicly traded company that can’t get a reasonable valuation based on progress achieved from the investment has to put the ceo on the hot seat. It could also be the handling of Amarex was really more problematic than we know. The email from Nader to Amarex to file the bla even if it is not done does not sound like a great leader. I hate that supported Nader so much, I really wanted the underdog to win.

I don’t think this is tied to a partnership or buy out deal that is pending.those deals have a way of leaking to a select few and the sp starts rising for seemingly no reason. That is not happening. I do think the door is wide open now for any offers, it could be Nader really had a very lofty expectation of not just a huge price tag but also other requirements for a deal. I think there must have been offers of all types that were never developed. It just seems impossible that this amount of data from fda trials stays off the radar of big pharma.

I have no idea what happens next but I am guessing there will be far less communication. I hope the removal of Nader means key people are more focused than ever on the development of this drug. I hope a real great partner come forward to really pick this up. No more fife funding Amarex screwups and carrots held in front of us.